Latest Development Pipeline News

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

Caprice Resources has launched a 5,000m drilling program at its Island Gold Project and expanded its West Arunta copper-niobium exploration tenure, supported by a $2.5 million capital raise. The company is sharpening its focus on high-grade gold assets in the Murchison goldfields while advancing large-scale greenfield projects.

Cedar Woods Properties has successfully extended its $330 million corporate finance facility, pushing the maturity of its three-year tranche to 2028 and its five-year tranche to 2030, reinforcing its financial stability.

RooLife Group Ltd (ASX:RLG) reports a remarkable 144% jump in Q2 FY25 sales revenue, driven by new online stores and strategic market entries into China and India. The company’s own branded health and wellness products are central to its growth strategy.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Comet Ridge has made significant strides in its Mahalo Gas Hub development, approving upstream FEED and progressing pipeline connections, supported by a strong cash position of $19.3 million. These developments position the company to address Australia's tightening east coast gas market.

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.

Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.

Strike Energy has taken a final investment decision on its South Erregulla 85 MW peaking gas power station and confirmed significant gas discoveries at Erregulla Deep and Walyering East-1, positioning the company for growth amid a strategic leadership transition.

NewPeak Metals has acquired the Allaru Vanadium Project in Queensland, marking a strategic pivot into critical minerals, supported by a planned $2–3 million capital raise via rights issue.